Clinical trials · Pennsylvania
Cancer clinical trials in Pennsylvania
We’re tracking 831 recruiting cancer studies with a site in Pennsylvania — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06926062Recruiting
Improving HPV vaccine communication in pharmacies
This study looks at whether training pharmacy staff in communication and vaccination workflows can improve HPV vaccine recommendations and uptake. If you are a parent or guardian of a child aged 9–17 who has not yet completed the HPV vaccine series, you may be eligible to participate.
University Park, PennsylvaniaAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Allentown, PennsylvaniaAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Danville, PennsylvaniaAges 18–59 - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Lancaster, PennsylvaniaAges 18 years+ - NCT06890598RecruitingPhase 3
Study of olomorasib for KRAS G12C-mutant lung cancer
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06872515Recruiting
Exercise before esophageal cancer surgery
This trial tests if doing supervised exercise before esophageal cancer surgery (called prehabilitation) helps people recover better. You would follow a personalized exercise plan for at least 2 weeks before your scheduled surgery.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06877884Recruiting
Cancer care data collection registry
This trial gathers information from your routine cancer care to help researchers learn more about real-world treatments and outcomes. No extra tests or procedures are required.
Paoli, PennsylvaniaAges 18–120 - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Easton, PennsylvaniaAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
Fountain Hill, PennsylvaniaAges 18 years+ - NCT06850623RecruitingPhase 2
Sound wave therapy plus chemo for advanced pancreatic cancer
This trial tests a new treatment that uses sound waves to help chemotherapy reach pancreatic tumors more effectively. It is for people with locally advanced pancreatic cancer that cannot be removed with surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06833073RecruitingPhase 2
Study of an mRNA vaccine and BCG for bladder cancer
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT06831552Recruiting
Supporting families of children with high-risk neuroblastoma
This study tests a resource intervention to help families with low income who have a child with high-risk neuroblastoma. It aims to reduce financial stress and improve care during treatment.
Philadelphia, PennsylvaniaAges Up to 17 years - NCT06807437RecruitingPhase 3
Testing lanreotide before pancreas surgery to prevent leaks
This trial tests if a medicine called lanreotide, given before surgery, can prevent a common complication (pancreatic leak) after removing part of the pancreas. It is for people with pancreatic cancer or a growth that could become cancer who are scheduled for a specific type of pancreas surgery.
Bethlehem, PennsylvaniaAges 18 years+ - NCT06809140RecruitingPhase 2
Bladder-sparing treatment for muscle-invasive bladder cancer
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06773936Enrolling by invitationPhase 2
Adding asciminib to usual care for adults with newly diagnosed Ph+ ALL
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
Pittsburgh, PennsylvaniaAges 60 years+ - NCT06780085RecruitingPhase 2
Study of new drugs for advanced lung cancer
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06774131RecruitingPhase 3
Study of UGN-104 for low-grade upper tract urothelial cancer
This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.
Hershey, PennsylvaniaAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Philadelphia, PennsylvaniaAges 18–100 - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Sellersville, PennsylvaniaAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06770855Recruiting
Focused treatment for kidney cancer that has responded to immunotherapy
This trial tests whether giving focused treatment (surgery or radiation) to all remaining cancer spots after immunotherapy can improve outcomes in kidney cancer. It's for people whose cancer has responded well to at least 6 months of immunotherapy and has only a few remaining spots.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06750094RecruitingPhase 3
Study of amivantamab plus FOLFIRI in colorectal cancer
This trial tests adding amivantamab to standard FOLFIRI chemotherapy for people with certain types of colorectal cancer that have already been treated once. It aims to see if this combination works better than another common treatment (cetuximab or bevacizumab plus FOLFIRI).
Penn Wynne, PennsylvaniaAges 18 years+ - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+
Cancer trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting cancer studies listed above.
- UPMC Hillman Cancer Center · 4 studies
- Fox Chase Cancer Center · 3 studies
- Thomas Jefferson University · 3 studies
- Geisinger Wyoming Valley/Henry Cancer Center · 2 studies
- MidLantic Urology · 2 studies
- Abramson Cancer Center of the University of Pennsylvania
- Abramson Cancer Center of The University of Pennsylvania
- Allegheny General Hospital
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Pennsylvania?
- Yes. We're currently tracking 831 recruiting cancer studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.